Abstract: A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2, wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is ? times by mass to 4 times by mass as that of the rosin-based resin.

Abstract: Device structure 100 for iontophoresis provides electrode 101 and electrically conductive layer 102. Electrically conductive layer 102 contains active ingredient D and basic water swelling methacrylate copolymer P1 and/or acidic water swelling methacrylate copolymer P2. Electrode 101 and electrically conductive layer 102 are placed into a hollow of backing 103 and electrode terminal 104 is connected to electrode 101 through backing 103. Adhesive layer 105 is set around backing 103, and liner 106 to be removed when using the device, is placed so as to cover the hollow of backing 103.

Abstract: A transdermal preparation is provided that contains risperidone and/or a pharmaceutically acceptable salt thereof as a drug, and the amount of the drug is 1 to 20 parts by mass based on 100 parts by mass of the total mass of the preparation. The skin permeation rate of the preparation is 0.5 to 30 ?g/cm2/hour, and the drug diffusion coefficient of the preparation in the skin is 1.2×10?6 to 10.0×10?6 cm/hour.

Abstract: The present invention relates to a transdermal preparation having a backing and an adhesive layer laminated on the backing, wherein the adhesive layer contains 4E indolone and a physiologically active compound.

Abstract: A method for storing a transdermally/transmucosally absorbable preparation, comprising keeping a transdermally/transmucosally absorbable preparation enclosed in a container in a low oxygen atmosphere, the transdermally/transmucosally absorbable preparation comprising a drug whose molecule has an amino group substituted with a lower alkyl group.

Abstract: By providing a non-liquid drug reservoir layer 2 having first and second principal surfaces and containing a drug and a polymer that is to be a base, a drug permeation layer 4 disposed at the first principal surface side of the drug reservoir layer 2 and being lower in permeability of the drug than the drug reservoir layer 2, and a first backing 3 with a bending resistance of 10 to 80 mm that is formed so as to cover a side surface of the drug reservoir layer, skin irritation can be reduced.

Abstract: The present invention aims to allow high molecular weight active ingredients to be contained in a coating agent substantially uniformly. For this purpose, a microneedle device 1 includes a microneedle base 2, and microneedles 3 capable of piercing a skin and being disposed on the microneedle base 2, wherein at least a part of a surface of the microneedles 3 and/or the microneedle base 2 is coated with a coating agent containing a high molecular weight active ingredient and a water-soluble polymer, and the content of the water-soluble polymer in the coating agent is 0.1 to 30% by weight, and the ratio of the content of the water-soluble polymer to the content of the high molecular weight active ingredient in the coating agent is 5:1 to 1:100.

Abstract: Provided is a microneedle device having a microneedle base and microneedles capable of piercing the skin and being from 300 ?m to 500 ?m in height disposed on the base, where at least a part of the surface of the microneedles and/or the microneedle base is coated with a coating agent containing an active ingredient and a coating carrier, and a blending ratio of the active ingredient and the coating carrier is 10:0.1 to 1:10. Also provided are methods for administering active ingredients efficiently and simply through the skin using the microneedle device.

Abstract: External preparations for athlete's foot treatment capable of enhancing patient's compliance and capable of reducing the symptom of rubefaction, comprising an anti-trichophyton drug mixed with at least one compound selected from among 1-menthol, menthol analogue compounds and bactericidal compounds.

Abstract: A pressure-sensitive adhesive tape package is provided. The pressure-sensitive adhesive tape package accommodates an adhesive tape having a support and an adhesive agent layer provided on one surface of the support, the adhesive tape being bent into a first portion and a second portion such that the adhesive agent layer faces outward. Moreover, the pressure-sensitive adhesive tape package can include a first release sheet releasably attached to the adhesive agent layer of the first portion of the adhesive tape, and a second release sheet releasably attached to the adhesive agent layer of the second portion of the adhesive tape to seal the adhesive tape with the first release sheet between the first and second release sheets. In this configuration, the conventionally existing package can be eliminated. Moreover, when the second release sheet is removed from the adhesive agent layer of the second portion of the adhesive tape, half of the adhesive agent layer is exposed.

Abstract: A pressure-sensitive adhesive tape package is described in which while easiness in applying the adhesive tape is pursued, an effect of saving in resources can be obtained. The pressure-sensitive adhesive tape package accommodates an adhesive tape having a support and an adhesive agent layer provided on one surface of the support, and includes a release sheet releasably attached to the adhesive agent layer. Moreover, in the pressure-sensitive adhesive tape package, the release sheet is bent along a predetermined bending line with the adhesive tape, and the adhesive tape is sealed inside of the bent release sheet.

Abstract: An adhesive patch containing a non-steroidal anti-inflammatory agent, comprising a support and an adhesive layer laminated on this support, wherein the adhesive layer contains a non-steroidal anti-inflammatory agent having a carboxyl group or its salt, and polyethylene glycol having an average molecular weight of 1000 or more.

Abstract: A preparation for external use which, even when ingredients such as a drug, absorption accelerator, and plasticizer are contained therein in a large amount, is excellent in pressure-sensitive adhesive properties including cohesive force and which, when a drug is contained therein, enables the drug to have excellent percutaneous absorbability. The preparation for external use includes a pressure-sensitive-adhesive matrix layer, wherein the pressure-sensitive-adhesive matrix layer comprises a pressure-sensitive adhesive base comprising a hydroxylated polymer, a boron compound, and silicic acid.

Abstract: An adhesive article comprising a backing and an adhesive layer disposed on at least one side of the backing, wherein the adhesive layer is formed from an adhesive base that contains substantially no gelatin and does contain readily soluble agar.

Abstract: Provided is a patch 1 containing a backing layer 2 and a pressure-sensitive adhesive layer 3 formed on the backing layer 2, where the pressure-sensitive adhesive layer 3 contains (i) ropinirole and a metal salt produced by the reaction of a ropinirole acid adduct and a metal ion containing desalting agent in an equivalent mole or less to the acid adduct and (ii) an adhesive base free of a hydroxyl group and a carboxy group.

Abstract: Disclosed is a transdermally absorbable preparation in which the crystallization of a medicinal agent can be prevented even when the medicinal agent has poor solubility in a base material and is contained in the base material at a high concentration, and which exhibits excellent long-term stability and transdermal absorbability of the medicinal agent. By adding a complex of an organic acid and an organic acid salt and a medicinal agent to a base material, it becomes possible to produce a transdermally absorbable preparation in which the crystallization of the medicinal agent can be prevented and which has excellent preparation properties and transdermal absorbability. Also disclosed is use of a complex of an organic and an organic acid salt for preventing the crystallization of a medicinal agent in a transdermally absorbable preparation.